REMARKS

Claims 1-3, 5-8, 12, 14, 16 and 18 are pending in this application. Upon entry of this amendment, claims 1-3, 5-8, 12, 14, 16, 18, and 25 will be pending, claims 1 and 12 having been amended and claim 25 added in this amendment. Support for the amendments to claims 1 and 12 may be found in the specification, paragraph [0090], and Fig. 7, for example. Support for new claim 25 may be found in the specification, paragraphs [0087], [0090], and Fig. 7, for example. Accordingly, there are no issues of new matter.

Applicants thank Examiner Toth for the courtesies extended to Applicants' representative, the undersigned, during the telephone interview on August 30, 2007, in which the 35 USC 103 rejections were discussed. Applicants' representative explained the differences between the claimed invention and the cited references, in particular with respect to the claimed display unit showing a prescription with a mark. Examiner Toth stated that, based on Applicants' representative's explanation, the cited references do not appear to teach or suggest the claimed display unit showing a prescription with a mark. Examiner Toth suggested, however, that to make the distinction clearer, the claims should be amended to describe the positioning of the mark.

Accordingly, Applicants have amended claim 1 to recite "wherein the display unit further shows a prescription with a mark, wherein the position of the mark on the graph represents a correlation between the calculated index and the measured blood pressure of the subject."

Applicants have similarly amended claim 12 to recite "wherein the display unit further shows a prescription with a mark, where the position of the mark on the graph represents the correlation between the at least two of the different indices."

Claims 1-3, 5, 6, 12, and 14 stand rejected under 35 USC 103(a) as being unpatentable over Ogura (USPA 2003/0167014) in view of Utsugi (USPA 2001/0056228) and Kodama (USPA 2003/0013988). Claims 7 and 8 stand rejected under 35 USC 103(a) as being unpatentable over Ogura in view of Utsugi and Kodama further in view of Hatschek (US

5,309,916). Claims 16 and 18 stand rejected under 35 USC 103(a) as being unpatentable over Ogura in view of Utsugi and Kodama further in view of Tanaka (USPA 2004/0077960).

Applicants traverse the rejections.

As discussed during the interview, Kodama, which is the only reference cited as

disclosing a prescription with a mark, does not disclose or suggest the above recited features of

amended claims 1 and 12. Hence, combining the cited references fails to disclose or suggest the

above recited features. Accordingly, claims 1 and 12 are allowable. Claims 2, 3, 5-8, and 25,

which depend either directly or indirectly from claim 1, and claims 14, 16, and 18, which depend either directly or indirectly from claim 12, are allowable at least by virtue of their dependency.

Applicants solicit early action in the form of a Notice of Allowance.

In the event that the transmittal letter is separated from this document and the Patent and

Trademark Office determines that an extension and/or other relief is required, Applicants petition

for any required relief including extensions of time and authorize the Commissioner to charge $% \left(1\right) =\left(1\right) \left(1\right) \left$

the cost of such petitions and/or other fees due in connection with the filing of this document to

Deposit Account No. 03-1952 referencing Docket No. 163852020000.

Respectfully submitted,

Dated: September 4, 2007

Cassadia J

Cassandra T. Swain, Ph.I Registration No. 48,361

Morrison & Foerster LLP

1650 Tysons Boulevard, Suite 400

McLean, Virginia 22102 Telephone: (703) 760-7796

Facsimile: (703) 760-7777

6